Reevaluating ALT 39 U/L: Updated Thresholds and Evidence‑Based Management

Updated Reference Ranges

The traditional upper‑limit for ALT is considered too high because it was derived from populations that included undiagnosed non‑alcoholic fatty liver disease (NAFLD). 1, 2
Evidence‑based healthy ALT thresholds are 30–36 U/L for males and 19–25 U/L for females. 1

The absolute magnitude of ALT elevation does not predict prognosis; the underlying liver disease determines outcomes. 2, 3
Major chronic liver diseases (NAFLD, alcohol‑related liver disease, hepatitis C) often present with only mild ALT rises yet can progress to end‑stage liver disease if left undiagnosed. 2, 3
Patients with chronic hepatitis C may have normal ALT but still face a ≈ 10‑year risk of cirrhosis if untreated; conversely, acute hepatitis A with ALT > 1000 U/L usually resolves completely. 2, 3

Do not repeat ALT solely to see if it normalises; in a cohort, 84 % remained abnormal after 1 month and 75 % after 2 years. 4, 5

Follow‑up interval	Percentage with persistent abnormal ALT
1 month	84 %
2 years	75 %

The first abnormal ALT result should prompt immediate investigation of underlying aetiology. 4, 5

Obtain a detailed history focusing on metabolic risk factors (BMI, central obesity, hypertension, diabetes/insulin resistance, dyslipidaemia), alcohol consumption (units/week, AUDIT‑C screening), viral hepatitis exposure (country of birth, injection‑drug use, parental infection), medication/supplement use, and family history of liver disease. 4, 5
Physical examination should include BMI calculation and abdominal assessment for hepatosplenomegaly, ascites, or stigmata of chronic liver disease. 4, 5

Hepatitis B surface antigen (HBsAg)
Hepatitis C antibody (followed by HCV RNA PCR if positive)
Fasting glucose and lipid profile
Ferritin and transferrin saturation (screen for haemochromatosis when saturation > 45 %)
Immunoglobulin G and autoantibodies (ANA, ASMA for autoimmune hepatitis)
Anti‑mitochondrial antibody (if cholestatic pattern) 4, 5

Metabolic syndrome present (obesity, diabetes, dyslipidaemia): an ALT of 39 U/L suggests possible NAFLD; consider liver ultrasound and non‑invasive fibrosis assessment. 1, 3, 4
Positive viral hepatitis markers: refer promptly to a hepatology specialist. 5
Positive autoimmune or cholestatic markers: refer according to local specialist pathways. 5

Assuming that a “mildly elevated” or “high‑normal” ALT is clinically insignificant is a common and dangerous error; many patients with significant fibrosis have ALT values within the conventional normal range. 1, 2, 3

Chronic hepatitis B treatment guidelines already recognise ALT > 30 U/L in males and > 19 U/L in females as clinically significant. 1, 3

Investigate the cause now rather than adopting a “watch‑and‑wait” strategy; the clinical context (metabolic risk, viral hepatitis exposure, alcohol use) determines the relevance of an ALT 39 U/L more than the absolute number. 4, 5, 2, 3
Early identification and treatment of reversible conditions such as viral hepatitis, NAFLD, or autoimmune liver disease can prevent progression to cirrhosis and improve long‑term outcomes. 2, 3